secwatch.observer — SEC 8-K summary
======================================

Issuer:     Surrozen, Inc./DE (SRZN)
CIK:        0001824893
Form:       8-K
Filed at:   2026-03-23T23:59:59+00:00
Accession:  0001193125-26-119757
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Surrozen reports FY2025 net loss $242M; cash $89.2M; expects IND for SZN-8141 in H2 2026
--------------------------------------------------------------------------------

- Cash and equivalents $89.2M at Dec 31, 2025, up from $34.6M year-end 2024; additional $30.2M raised in early 2026 via ATM and warrant exercises.
- Full year net loss $242.0M ($32.37 per share) vs $63.6M in 2024, driven by non-cash PIPE-related charges (tranche liability, warrant revaluation).
- No collaboration revenue in 2025 vs $10M in 2024; research service revenue from terminated TCGFB deal was $3.5M.
- Received $5M milestone from Boehringer Ingelheim for SZN-413 after successful IND-enabling GLP tox study.
- On track to submit IND for SZN-8141 (retinal disease) to FDA in H2 2026; will present at ARVO in May 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824893/000119312526119757/0001193125-26-119757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824893/000119312526119757/srzn-20260323.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-119757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer